Expensive cytotoxic chemotherapy in the management of advanced cancers in the developing world

Oncology

Volumn 78, Issue 1, 2010, Pages 3-4

  Markman, Maurie ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADVANCED CANCER; CANCER CHEMOTHERAPY; DEVELOPING COUNTRY; DISEASE ASSOCIATION; EDITORIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; KENYA; OUTCOME ASSESSMENT; PALLIATIVE THERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; SURVIVAL RATE; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; DEVELOPING COUNTRIES; HUMANS; NEOPLASMS;

EID: 77649281367     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000292354     Document Type: Editorial

References (3)

1. Lingwood RJ, Boyle P, Milburn A, Ngoma T, Arbuthnott, J, McCaffrey R, Kerr SH, Kerr DJ: The challenge of cancer control in Africa. Nature Reviews Cancer 2008; 8: 398-403.
2. Strother RM, Gregory KM, Pastakia SD, Were P, Tenge C, Busakhala N, Jakait B, Schellhase EM, Rosmarin AG, Loehrer PJ: Retrospective analysis of the efficacy of gemcitabine for previously treated AIDS-associated Kaposi's Sarcoma in Western Kenya. Oncology 2010;78:5-11.
3. Einterz RM, Kelly CR, Mamlin JJ, Van Reken DE: Partnerships in international health: The Indiana University-Moi University experience. Infect Dis Clin North Am 1995; 9: 453-455.